Gene-eden, a broad range, natural antiviral supplement, may shrink tumors and strengthen the immune system

Acta Oncologica, 2010; 49: 397–399 LETTER TO THE EDITOR
Gene-Eden, a broad range, natural antiviral supplement, may shrink
tumors and strengthen the immune system
The Center for the Biology of Chronic Disease, Rochester, New York, USA To the Editor
increased in number. Concentration of red blood cells, Gene-Eden (by polyDNA) is a broad range, natural hemoglobin, hematocrit, lymphocytes, eosinophils and antiviral supplement that targets viruses during their basophils decreased by 21%, 23%, 10%, 78% and latent or chronic phase. The development of Gene- 100%, respectively. As a result, the original treatment Eden was inspired by Hanan Polansky’s discovery [1] was discontinued and a new chemotherapy treatment of the Starved Gene phenomenon. According to of capecitabine (Xeloda) was initiated. A week later, Polansky, the promoter/enhancer of certain common the patient began a treatment with Gene-Eden in viruses, such as Epstein Barr Virus (EBV), Cytomeg- addition to the chemotherapy. After fi ve weeks, a CT alovirus (CMV), and Herpes Simplex Virus (HSV), revealed a decrease of 35% in the tumor size, and a competes during latency with the promoter/enhancer decrease of 18% in the hepatic mass. Blood test of certain cellular genes for the limiting transcription showed an increase in the concentration of lympho- cytes (1.72ϫ103 cells/µl compared with 0.70ϫ103 BRCA1 are two cellular genes that bind this complex. cells/µl), eosinophils (0.11ϫ103 cells/µl compared Since GABP•p300/cbp transactivates these genes, with 0 cells/µl) and basophils (0.02ϫ103 cells/µl com- and since both genes encode a cell cycle suppressor, pared with 0 cells/µl), the new numbers were in the the presence of a high copy number of a sequestering normal range and at levels similar to those observed latent virus in the nucleus diminishes the expression prior to the initiation of the fi rst chemotherapy treat- of the Rb and BRCA1 genes, which leads to excessive ment. In addition, the patient gained weight, felt a relief in pain, was able to get up from bed alone and The patient is a 61-year-old female with an inop- to walk around and was fi lling better in general.
Acta Oncol Downloaded from informahealthcare.com by 77.127.45.3 on 08/02/13 erable pancreatic carcinoma in the head of the pan- The question is whether these remarkable results creas with vascular involvement. The patient was should be attributed to the new chemotherapy treat- receiving chemotherapy treatment of gemcitabine ment with capecitabine alone, or whether the addition (Gemzar) + oxaliplatin (Eloxatin) + erlotinib of Gene-Eden had a major role in producing the (Tarceva) for a period of two months. During that observed remission. According to latest studies, treat- time, test results and medical observations were ments with capecitabine alone or in combination with showing a general worsening in the patient condition. other chemotherapy agents achieved results that range The pancreatic tumor increased by 64% and was between stable disease and mild or partial responses. progressing towards mesenteric root (the size of the There are only a few studies to demonstrate physical tumor was measured by the use of unidimensional tumor shrinkage. One such study [2], which examined measurements and the sum of the longest diameters).
the effect of capecitabine on tumor size, reports that Hepatic mass increased by 22% and new hypodense only three of the 42 patients (7%) treated with capecit- masses were observed. Lymph nods were enlarged and abine for advanced or metastatic pancreatic cancer Correspondence: Hanan Polansky, The Center for the Biology of Chronic Disease, 2230 Elmwood Avenue, Rochester, New York, 14620, USA. Tel: +1 585 200 5546. Fax: +1 585 200 5545. E-mail: [email protected] (Received 10 September 2009; accepted 24 October 2009) ISSN 0284-186X print/ISSN 1651-226X online 2010 Informa UK Ltd. (Informa Healthcare, Taylor & Francis AS) showed any reduction is tumor size after median treat- Conclusion
ment time of 85 days. In our case, the decrease in According to the Starved Gene discovery, latent tumor size was visible in the single patient that was viruses can cause pancreatic cancer, and an antiviral treated, and after only fi ve weeks of treatment. In light supplement that targets latent viruses can be effective of that study, it is unlikely that the capecitabine treat- in treating the disease. Gene-Eden is a promising ment alone was responsible for the observed remission broad range, natural antiviral supplement that targets in our case. The possibility that Gene-Eden treatment latent viruses. The results of this study show that the contributed to the effect should be considered.
addition of Gene-Eden to chemotherapy may have In addition to the decrease in tumor size, blood participated in shrinking the tumor and in strength- tests showed that the addition of Gene-Eden had a ening the immune system in a case with poor prog- nosis. Such participation is consistent with the Studies report that chemotherapy can have different expected effects of Gene-Eden on pancreatic cancer immuno-suppressive effects, and specifi cally, can according to the Starved Gene discovery.
decrease the number of white blood cells, including lymphocytes and leukocytes. For instance, one study [3] examined the infl uence of chemotherapy on lym- Declaration of interest: The authors report no
phocytes depletion in 258 breast cancer patients. In all confl icts of interest. The authors alone are respon- patients, grade 3 or grade 4 lymphopenia was observed sible for the content and writing of the paper.
after fi ve cycles of treatment. Another study [4] revealed a loss of antibodies against measles and rubella in chil- References
dren treated with intensive chemotherapy. A third study [1] Polansky H. Cancer, Microcompetition with foreign DNA [5] compared the immunity conditions of 34 patients and the origin of chronic disease. Rochester, New York: with breast cancer after chemotherapy and radiother- apy treatment with those of patients with primary breast [2] Cartwright TH, Cohn A, Varkey JA, Chen YM, Szatrowski cancer. T cells proportions were signifi cantly lower in TP, Cox JV, et al. Phase II study of oral capecitabine in patients who received the treatment. (Note that in this patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002;20:160–4.
study the treatment included radiotherapy, which is [3] Tolaney SM, Najita J, Winer EP, Burstein HJ. Lymphopenia known to have an immuno-suppressive effect.) associated with adjuvant anthracycline/taxane regimens. Clin Capecitabine has also been reported to cause immuno-suppression in cancer patients. A study [6] [4] Nilsson A, De Milito A, Engström P, Nordin M, Narita M, examined the effi ciency of combined therapy of beva- Grillner L, et al. Current chemotherapy protocols for child-hood acute lymphoblastic leukemia induce loss of humoral cizumab, capecitabine and gemcitabine on 50 patients immunity to viral vaccination antigens. Pediatrics 2002;109: with advanced pancreatic cancer. Toxicity results revealed a grade 3 neutropaenia in 22% of the patients. [5] Solomayer EF, Feuerer M, Bai L, Umansky V, Beckhove P, Another study [7] showed a 30.5% lymphocytopenia Meyberg GC, et al. Infl uence of adjuvant hormone therapy following treatment with capecitabine in 60 patients and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer. Clin Cancer Res with advanced/metastatic colorectal cancer. A third study [8] reported grade 3 and 4 leucopenia in 66% [6] Javle M, Yu J, Garrett C, Pande A, Kuvshinoff B, Litwin A Acta Oncol Downloaded from informahealthcare.com by 77.127.45.3 on 08/02/13 of the patients with metastatic breast cancer following et al. Bevacizumab combined with gemcitabine and capecit- treatment with capecitabine-docetaxel. A fourth study abine for advanced pancreatic cancer: A phase II study. Br J [9], which examined the effect of an oral vinorelbine Cancer 2009;100:1842–5. Epub 2009 Jun 2. [7] Sakamoto J, Kondo Y, Takemiya S, Sakamoto N, Nishisho I; and capecitabine combination on 54 patients with Clinical Study Group of Capecitabine. A phase II Japanese metastatic breast cancer, reported grade 3 and grade study of a modifi ed capecitabine regimen for advanced or 4 neutropaenia in 49% of the patients. These and oth- metastatic colorectal cancer. Anticancer Drugs 2004;15: ers studies [10–13] suggest that capecitabine can be immuno-suppressive. The results of the treatment [8] Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Schneeweiss A, et al. Phase III study of gemcitabine plus with capecitabine (Xeloda) + Gene-Eden reveal a docetaxel compared with capecitabine plus docetaxel for positive effect on immune markers. We propose that anthracycline-pretreated patients with metastatic breast the addition of Gene-Eden facilitated this effect. cancer. J Clin Oncol 2009;27:1753–60.
Considering the observed lymphopenia and leucope- [9] ubiana-Mathieu N, Bougnoux P, Becquart D, Chan A, nia in the above cited studies, it is very unlikely that Conte PF, Majois F, et al. All-oral combination of oral vinorelbine and capecitabine as fi rst-line chemotherapy in capecitabine alone caused the positive effect. Since HER2-negative metastatic breast cancer: An International capecitabine therapy is known to cause lymphopenia, Phase II Trial. Br J Cancer 2009;101:232–7. Epub 2009 we would like to suggest that the improvement in lymphocytes concentration in our case is due to the ieder T, Weitzel C, Schölmerich J, Landthaler M, Stolz W. Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fl uorouracil N, Jiang W, Li H, Liu Z, Xu X, Wang M. Triweekly prodrug for metastasizing colorectal carcinoma: A lesson for oxaliplatin plus oral capecitabine as fi rst-line chemotherapy the pathogenesis of malignant melanoma? Dermatology in elderly patients with advanced gastric cancer. Am J Clin M. Pharmacological and clinical properties of [13] Wagstaff AJ, Ibbotson T, Goa KL. Capecitabine: A review of Xeloda (Capecitabine), a new oral active derivative of fl uor- its pharmacology and therapeutic effi cacy in the manage- opyrimidine. Nippon Yakurigaku Zasshi 2003;122:549–53.
ment of advanced breast cancer. Drugs 2003;63:217–36.
Acta Oncol Downloaded from informahealthcare.com by 77.127.45.3 on 08/02/13

Source: http://www.buy-gene-eden.com/acta-gene-eden.pdf